Hunan New Wellful Co.,Ltd. (Shanghai Stock Exchange: 600975.SS) is a leading Chinese manufacturer and supplier of pharmaceutical preparations and medical devices, specializing in oncology, anti-infection, and nervous system therapeutics. The company offers a diverse portfolio of products including small-volume injections such as irinotecan hydrochloride for colorectal cancer treatment; tablets and capsules like entecavir for hepatitis B; and medical devices encompassing infusion sets, syringes, and blood bags, marketed under brands like New Wellful and Wellful. Founded in 1958 and headquartered in Xiangtan, Hunan province, it operates primarily in China with distribution networks serving hospitals, pharmacies, and healthcare institutions nationwide.
In recent developments, Hunan New Wellful expanded its production capacity through a major green manufacturing project completed in 2024, enhancing output for key oncology drugs amid rising demand. The company formed strategic partnerships with leading pharmaceutical distributors in 2025 to bolster market penetration in tier-2 and tier-3 cities, while launching new formulations of piperacillin sodium tazobactam for anti-infection applications. Additionally, it pursued R&D collaborations with academic institutions for innovative drug delivery systems, positioning itself for growth in the competitive domestic biopharma sector.